>>Signaling Pathways>> Immunology/Inflammation>> 15-lipoxygenase>>Cannabidiol dimethyl ether

Cannabidiol dimethyl ether (Synonyms: CBDD,Cannabidiol-2',6'-dimethyl ether)

Catalog No.GC13816

Pomalidomide - Peg2-azide is a synthetic E3 ligand -linker conjugate containing Pomalidomide based cereblon ligand and 2-unit PEG linker.

Products are for research use only. Not for human use. We do not sell to patients.

Cannabidiol dimethyl ether Chemical Structure

Cas No.: 1242-67-7

Size 가격 재고 수량
1mg
US$44.00
재고 있음
5mg
US$195.00
재고 있음
10mg
US$342.00
재고 있음
50mg
US$1,500.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com


고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Pomalidomide - Peg2-azide is a synthetic E3 ligand -linker conjugate containing Pomalidomide based cereblon ligand and 2-unit PEG linker. PROTAC can be synthesized to target protein degradation[1].

The IC50 value of protac compound 21[(BRD4 BD1, IC50 = 41.8 nM) composed of Pomalidomide - Peg2-azide] was 0.81 µM in inhibiting THP-1 cell line growth. At the concentration of 1 µM, compound 21 can effectively degrade BRD4 protein and inhibit c-Myc[1].

References:
[1]. Zhang F, Wu Z, et,al. Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide. Bioorg Med Chem. 2020 Jan 1;28(1):115228. doi: 10.1016/j.bmc.2019.115228. Epub 2019 Nov 30. PMID: 31813613.

리뷰

Review for Cannabidiol dimethyl ether

Average Rating: 5 ★★★★★ (Based on Reviews and 11 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Cannabidiol dimethyl ether

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.